Cell Therapies — Pipeline, Approvals, Sponsors

Living-cell therapeutics: CAR-T (engineered T cells with chimeric antigen receptors), TCR-T (T cell receptor engineered), TILs (tumour-infiltrating lymphocytes), NK cells. Highly active in hematologic malignancies, moving into solid tumours.

Marketed leaders

• 2024-01-01 — LIFILEUCEL
• 2022-01-01 — TABELECLEUCEL · Oncology
• 2018-01-01 — DARVADSTROCEL · Immunology
• 2018-01-01 — Kymriah · Novartis Pharmaceuticals Corporation · CD19-directed Chimeric Antigen Receptor [EPC] · Oncology
• — SIPULEUCEL-T · Autologous Cellular Immunotherapy [EPC]

Recent approvals (last 30 days)

No approvals in the last 30 days.

Upcoming PDUFA (next 180 days)

No upcoming PDUFA in next 180 days.

Top sponsors in this modality

1. · 5 cell therapies
2. Novartis Pharmaceuticals Corporation · 1 cell therapies

Drug classes within Cell Therapies

• Autologous Cellular Immunotherapy [EPC] · 1
• CD19-directed Chimeric Antigen Receptor [EPC] · 1

Subscribe to ongoing alerts

Push every new cell therapies event into your RSS reader:

• Cell Therapies firehose — RSS
• Recent Cell Therapies approvals only
• Upcoming Cell Therapies PDUFA only

Other modalities